Applied Therapeutics IncNASDAQ:APLT
- LAST PRICE4.5100
- TODAY'S CHANGE (%)0.1300 (2.9680%)
- Bid / Lots4.3000/ 1
- Ask / Lots4.5800/ 5
- Open / Previous Close4.3500 / 4.3800
- Day Range
- 52 Week Range
- Volume749,977
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APLT |
|---|---|---|
| 09:32 ET | 6255 | 4.315 |
| 09:34 ET | 300 | 4.32 |
| 09:36 ET | 300 | 4.31 |
| 09:38 ET | 200 | 4.31 |
| 09:39 ET | 300 | 4.31 |
| 09:41 ET | 200 | 4.31 |
| 09:43 ET | 400 | 4.31 |
| 09:45 ET | 2194 | 4.3234 |
| 09:48 ET | 7552 | 4.3499 |
| 09:50 ET | 458 | 4.335 |
| 09:52 ET | 3053 | 4.33 |
| 09:56 ET | 800 | 4.315 |
| 09:57 ET | 1516 | 4.32 |
| 10:06 ET | 961 | 4.315 |
| 10:08 ET | 100 | 4.31 |
| 10:15 ET | 1531 | 4.32 |
| 10:17 ET | 100 | 4.33 |
| 10:19 ET | 400 | 4.34 |
| 10:21 ET | 1432 | 4.33 |
| 10:26 ET | 2000 | 4.3399 |
| 10:30 ET | 500 | 4.33 |
| 10:33 ET | 1958 | 4.34 |
| 10:37 ET | 1031 | 4.335 |
| 10:39 ET | 6827 | 4.33 |
| 10:42 ET | 917 | 4.345 |
| 10:44 ET | 4200 | 4.35 |
| 10:46 ET | 1800 | 4.345 |
| 10:48 ET | 700 | 4.35 |
| 10:50 ET | 6711 | 4.39 |
| 10:51 ET | 3523 | 4.39 |
| 10:53 ET | 6538 | 4.39 |
| 10:55 ET | 7803 | 4.395 |
| 10:57 ET | 5900 | 4.395 |
| 11:00 ET | 4773 | 4.39 |
| 11:02 ET | 2300 | 4.365 |
| 11:04 ET | 1212 | 4.385 |
| 11:06 ET | 700 | 4.385 |
| 11:08 ET | 1000 | 4.3811 |
| 11:09 ET | 1200 | 4.4 |
| 11:11 ET | 300 | 4.4 |
| 11:13 ET | 529 | 4.3917 |
| 11:15 ET | 200 | 4.395 |
| 11:18 ET | 11317 | 4.43 |
| 11:20 ET | 300 | 4.43 |
| 11:22 ET | 200 | 4.43 |
| 11:24 ET | 2402 | 4.42 |
| 11:26 ET | 473 | 4.425 |
| 11:27 ET | 482 | 4.425 |
| 11:29 ET | 3550 | 4.41 |
| 11:33 ET | 100 | 4.42 |
| 11:36 ET | 300 | 4.415 |
| 11:38 ET | 1080 | 4.42 |
| 11:40 ET | 200 | 4.42 |
| 11:42 ET | 975 | 4.43 |
| 11:44 ET | 1323 | 4.43 |
| 11:45 ET | 2125 | 4.425 |
| 11:47 ET | 1864 | 4.43 |
| 11:49 ET | 6539 | 4.43 |
| 11:51 ET | 2144 | 4.43 |
| 11:54 ET | 550 | 4.43 |
| 11:56 ET | 28453 | 4.435 |
| 11:58 ET | 2505 | 4.41 |
| 12:00 ET | 200 | 4.42 |
| 12:02 ET | 2069 | 4.405 |
| 12:03 ET | 511 | 4.41 |
| 12:05 ET | 864 | 4.4 |
| 12:07 ET | 300 | 4.41 |
| 12:09 ET | 1074 | 4.41 |
| 12:12 ET | 300 | 4.41 |
| 12:14 ET | 500 | 4.4 |
| 12:16 ET | 5706 | 4.395 |
| 12:18 ET | 527 | 4.4 |
| 12:20 ET | 5707 | 4.405 |
| 12:21 ET | 800 | 4.405 |
| 12:23 ET | 800 | 4.41 |
| 12:25 ET | 7788 | 4.43 |
| 12:27 ET | 5572 | 4.41 |
| 12:30 ET | 1200 | 4.4 |
| 12:32 ET | 2454 | 4.39 |
| 12:36 ET | 400 | 4.395 |
| 12:38 ET | 910 | 4.405 |
| 12:39 ET | 931 | 4.39 |
| 12:41 ET | 216 | 4.4 |
| 12:43 ET | 100 | 4.39 |
| 12:45 ET | 200 | 4.39 |
| 12:48 ET | 3117 | 4.37 |
| 12:50 ET | 200 | 4.39 |
| 12:52 ET | 300 | 4.39 |
| 12:54 ET | 900 | 4.39 |
| 12:56 ET | 100 | 4.39 |
| 12:57 ET | 100 | 4.4 |
| 12:59 ET | 500 | 4.4 |
| 01:01 ET | 26308 | 4.41 |
| 01:03 ET | 600 | 4.41 |
| 01:06 ET | 90996 | 4.41 |
| 01:08 ET | 3665 | 4.41 |
| 01:10 ET | 2313 | 4.4 |
| 01:14 ET | 100 | 4.4 |
| 01:15 ET | 3314 | 4.415 |
| 01:17 ET | 400 | 4.43 |
| 01:19 ET | 1200 | 4.42 |
| 01:21 ET | 800 | 4.44 |
| 01:24 ET | 300 | 4.45 |
| 01:26 ET | 1500 | 4.47 |
| 01:28 ET | 3393 | 4.47 |
| 01:30 ET | 200 | 4.46 |
| 01:32 ET | 3900 | 4.465 |
| 01:33 ET | 996 | 4.46 |
| 01:35 ET | 300 | 4.4629 |
| 01:37 ET | 437 | 4.47 |
| 01:39 ET | 1045 | 4.4614 |
| 01:42 ET | 400 | 4.47 |
| 01:44 ET | 3504 | 4.47 |
| 01:46 ET | 200 | 4.47 |
| 01:48 ET | 3057 | 4.455 |
| 01:50 ET | 3844 | 4.455 |
| 01:53 ET | 1288 | 4.46 |
| 01:55 ET | 1932 | 4.455 |
| 01:57 ET | 100 | 4.455 |
| 02:00 ET | 200 | 4.45 |
| 02:04 ET | 100 | 4.45 |
| 02:06 ET | 6047 | 4.43 |
| 02:08 ET | 4150 | 4.43 |
| 02:09 ET | 100 | 4.44 |
| 02:11 ET | 6084 | 4.45 |
| 02:13 ET | 100 | 4.44 |
| 02:15 ET | 500 | 4.45 |
| 02:18 ET | 1800 | 4.45 |
| 02:20 ET | 400 | 4.45 |
| 02:22 ET | 6101 | 4.43 |
| 02:24 ET | 100 | 4.43 |
| 02:26 ET | 500 | 4.43 |
| 02:27 ET | 400 | 4.43 |
| 02:29 ET | 200 | 4.42 |
| 02:31 ET | 200 | 4.43 |
| 02:33 ET | 2664 | 4.425 |
| 02:36 ET | 300 | 4.43 |
| 02:38 ET | 3975 | 4.415 |
| 02:40 ET | 800 | 4.415 |
| 02:42 ET | 699 | 4.415 |
| 02:44 ET | 3730 | 4.4 |
| 02:45 ET | 100 | 4.4 |
| 02:47 ET | 100 | 4.4 |
| 02:51 ET | 100 | 4.4 |
| 02:54 ET | 500 | 4.41 |
| 02:56 ET | 3359 | 4.41 |
| 02:58 ET | 1400 | 4.41 |
| 03:00 ET | 3798 | 4.39 |
| 03:02 ET | 607 | 4.39 |
| 03:03 ET | 2300 | 4.39 |
| 03:05 ET | 3462 | 4.41 |
| 03:07 ET | 1700 | 4.41 |
| 03:09 ET | 2600 | 4.41 |
| 03:12 ET | 2993 | 4.41 |
| 03:14 ET | 4323 | 4.415 |
| 03:16 ET | 600 | 4.415 |
| 03:18 ET | 600 | 4.41 |
| 03:20 ET | 1078 | 4.415 |
| 03:21 ET | 10098 | 4.395 |
| 03:23 ET | 4282 | 4.395 |
| 03:25 ET | 1593 | 4.395 |
| 03:27 ET | 4567 | 4.39 |
| 03:32 ET | 5853 | 4.4 |
| 03:34 ET | 900 | 4.395 |
| 03:36 ET | 900 | 4.4 |
| 03:38 ET | 23753 | 4.395 |
| 03:39 ET | 14506 | 4.42 |
| 03:41 ET | 3421 | 4.43 |
| 03:43 ET | 500 | 4.44 |
| 03:45 ET | 4187 | 4.46 |
| 03:48 ET | 7387 | 4.46 |
| 03:50 ET | 1393 | 4.47 |
| 03:52 ET | 2797 | 4.47 |
| 03:54 ET | 700 | 4.49 |
| 03:56 ET | 9556 | 4.495 |
| 03:57 ET | 24143 | 4.49 |
| 03:59 ET | 36791 | 4.51 |
Jul 1, 2024
Applied Therapeutics Added to Russell 3000(R) Index, from 7:00AM ET on Monday Jul 01, 2024 by Dow Jones
7:00AM ET on Monday Jul 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Applied Therapeutics Inc | 515.3M | -2.4x | --- |
Iteos Therapeutics Inc | 506.3M | -3.7x | --- |
Northwest Biotherapeutics Inc | 520.7M | -6.8x | --- |
Annexon Inc | 464.6M | -3.1x | --- |
Kalvista Pharmaceuticals Inc | 497.4M | -3.8x | --- |
Astria Therapeutics Inc | 498.6M | -3.9x | --- |
Company Information
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Contact Information
- Headquarters
- 545 FIFTH AVENUE, SUITE 1400NEW YORK, NY, United States 10017
- Phone
- 212-220-9226
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Founder
- Shoshana Shendelman
- Chief Financial Officer and Principal Financial Officer, Director
- Leslie Funtleyder
- Chief Operating Officer and Chief Business Officer
- Constantine Chinoporos
- Chief Accounting Officer
- Catherine Thorpe
- Chief Commercial Officer
- Dale Hooks
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $515.3M |
|---|---|
Revenue (TTM) | $-477.0K |
Shares Outstanding | 114.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.99 |
EPS | $-1.91 |
Book Value | $-0.20 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
